Ekso Bionics Holdings, Inc. Stock

Equities

EKSO

US2826443010

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
1.28 USD +8.47% Intraday chart for Ekso Bionics Holdings, Inc. +5.79% -48.80%
Sales 2024 * 23.5M Sales 2025 * 30.5M Capitalization 22.92M
Net income 2024 * -9M Net income 2025 * -5M EV / Sales 2024 * 0.98 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.75 x
P/E ratio 2024 *
-2.61 x
P/E ratio 2025 *
-5.33 x
Employees 71
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.5%
More Fundamentals * Assessed data
Dynamic Chart
Certain Warrants of Ekso Bionics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2024. CI
Certain Common Stock of Ekso Bionics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2024. CI
HC Wainwright Trims Price Target on Ekso Bionics to $9.25 From $10, Keeps Buy Rating MT
Transcript : Ekso Bionics Holdings, Inc., Q4 2023 Earnings Call, Mar 04, 2024
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
HC Wainwright Adjusts Ekso Bionics Holdings' Price Target to $10 From $9, Keeps Buy Rating MT
Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR CI
Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 CI
Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal CI
Transcript : Ekso Bionics Holdings, Inc., Q3 2023 Earnings Call, Oct 26, 2023
Earnings Flash (EKSO) EKSO BIONICS HOLDINGS Posts Q3 Revenue $4.6M, vs. Street Est of $4.53M MT
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Ekso Bionics Holdings, Inc., Q2 2023 Earnings Call, Jul 27, 2023
Earnings Flash (EKSO) EKSO BIONICS HOLDINGS Reports Q2 Revenue $4.7M, vs. Street Est of $4.35M MT
More news
1 day+8.47%
1 week+5.79%
Current month-5.88%
1 month-11.72%
3 months-43.11%
6 months+60.00%
Current year-48.80%
More quotes
1 week
1.14
Extreme 1.14
1.34
1 month
1.14
Extreme 1.14
1.53
Current year
1.14
Extreme 1.14
3.13
1 year
0.62
Extreme 0.62
3.13
3 years
0.62
Extreme 0.62
6.13
5 years
0.62
Extreme 0.62
33.92
10 years
0.62
Extreme 0.62
330.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 21-03-31
Director of Finance/CFO 50 17-04-30
Chief Operating Officer 52 -
Members of the board TitleAgeSince
Director/Board Member 57 21-12-24
Director/Board Member 57 20-12-28
Director/Board Member 69 20-12-28
More insiders
Date Price Change Volume
24-04-25 1.28 +8.47% 105,061
24-04-24 1.18 +1.72% 25,894
24-04-23 1.16 -9.38% 130,377
24-04-22 1.28 -3.03% 132,388
24-04-19 1.32 +9.09% 54,021

Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT

More quotes
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.28 USD
Average target price
9.25 USD
Spread / Average Target
+622.66%
Consensus